Geron Corporation Securities Fraud Lawsuits
Analysis based on 48 articles · First reported Mar 13, 2025 · Last updated Apr 04, 2025
The market is negatively impacted by the alleged securities fraud by Geron Corporation, leading to a significant decline in its stock price. The ongoing class action lawsuits by firms like Levi & Korsinsky, The Gross Law Firm, and Robbins Geller Rudman & Dowd LLP create uncertainty for investors and highlight the importance of corporate transparency in the biotechnology sector.
Geron Corporation is facing multiple class action lawsuits for alleged securities fraud. Law firms including Levi & Korsinsky, The Gross Law Firm, and Robbins Geller Rudman & Dowd LLP are representing investors who suffered losses due to allegedly misleading statements made by Geron Corporation regarding the launch and growth potential of its drug, Rytello (imetelstat). The lawsuits claim that Geron Corporation minimized risks associated with Rytello's weekly monitoring requirement, seasonality, and existing competition, and that the drug lacked necessary market awareness. On February 26, 2025, Geron Corporation announced its Q4 2024 financial results, revealing that Rytello's growth had flattened, leading to a 32.07% drop in Geron Corporation's stock price. Investors have until May 12, 2025, to seek appointment as lead plaintiff in these lawsuits, which are filed in the United States — United States District Court for the Northern District of California.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard